Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP)’s share price shot up 3.8% on Wednesday . The stock traded as high as $11.30 and last traded at $11.23, with a volume of 251,113 shares changing hands. The stock had previously closed at $10.82.

Several equities analysts have recently commented on SCMP shares. Leerink Swann restated a “hold” rating on shares of Sucampo Pharmaceuticals in a research report on Friday, March 11th. Mizuho restated a “buy” rating on shares of Sucampo Pharmaceuticals in a research report on Wednesday, May 4th. Maxim Group boosted their price objective on Sucampo Pharmaceuticals from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, March 9th. Jefferies Group lowered their price objective on Sucampo Pharmaceuticals from $19.00 to $16.00 and set a “hold” rating on the stock in a research report on Wednesday, March 9th. Finally, WallachBeth Capital upgraded Sucampo Pharmaceuticals from a “hold” rating to a “buy” rating and set a $16.00 price objective on the stock in a research report on Thursday, May 5th. Four analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $21.00.

The firm has a 50 day moving average of $11.35 and a 200 day moving average of $12.23. The company has a market cap of $478.73 million and a P/E ratio of 22.24.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, May 4th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.02. The firm had revenue of $47.20 million for the quarter, compared to analysts’ expectations of $44.11 million. The company’s revenue was up 60.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.14 earnings per share. Equities analysts predict that Sucampo Pharmaceuticals Inc. will post $1.02 EPS for the current fiscal year.

Other large investors have recently bought and sold shares of the company. Systematic Financial Management LP raised its stake in Sucampo Pharmaceuticals by 18.1% in the fourth quarter. Systematic Financial Management LP now owns 101,745 shares of the biopharmaceutical company’s stock valued at $1,759,000 after buying an additional 15,590 shares during the last quarter. GSA Capital Partners LLP raised its stake in Sucampo Pharmaceuticals by 8.5% in the fourth quarter. GSA Capital Partners LLP now owns 219,881 shares of the biopharmaceutical company’s stock valued at $3,802,000 after buying an additional 17,172 shares during the last quarter. Globeflex Capital L P raised its stake in Sucampo Pharmaceuticals by 76.5% in the fourth quarter. Globeflex Capital L P now owns 65,588 shares of the biopharmaceutical company’s stock valued at $1,134,000 after buying an additional 28,431 shares during the last quarter. NorthCoast Asset Management LLC purchased a new stake in Sucampo Pharmaceuticals during the fourth quarter valued at about $1,130,000. Finally, Shell Asset Management Co. purchased a new stake in Sucampo Pharmaceuticals during the fourth quarter valued at about $1,324,000.

Sucampo Pharmaceuticals, Inc is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.